Novo Nordisk ends kidney disease trial, books $816 mln impairment in Q2 - Reuters

Reuters | June 26, 2024, 11:10 a.m. | Original
Novo Nordisk ends kidney disease trial, books $816 mln impairment in Q2 Reuters
Medtronic's longtime CFO Karen Parkhill to leave, join HP - Reuters Brazilian minister offers help for Portugal to tackle legacy of slavery - Reuters